Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 2Glioma 2Triple Negative Breast Neoplasms 1Recurrence 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Glioblastoma 1Endometrial Neoplasms 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Rituximab 24Cyclophosphamide 20fludarabine phosphate 16Mycophenolic Acid 13Filgrastim 12Cyclosporine 12Bortezomib 12Antilymphocyte Serum 11Whole-Body Irradiation 10Peripheral Blood Stem Cell Transplantation 10Tacrolimus 9Lenalidomide 9fludarabine 8Radiotherapy 7Methotrexate 7Cord Blood Stem Cell Transplantation 7Melphalan 6Busulfan 6venetoclax 5Etoposide 5tanespimycin 4ibrutinib 4Polymerase Chain Reaction 4Methylprednisolone 4Granulocyte Colony-Stimulating Factor 4Flow Cytometry 4ublituximab 3thymoglobulin 3sargramostim 3carfilzomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Mantle-Cell × TIC10 compound × Clear all
NCT02420795 2022-04-04

Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
16 enrolled 14 charts
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡